Abstract
Azole antimycotics are a well-known and important class of agents that are used in hospital practice, everyday health care, veterinary medicine and for crop protection. The era of azole fungicides began with the breakthrough of chlormidazole roughly 50 years ago. Since then, more than 20 drugs of this group, including triazoles, have been brought to the market. The specific chemical structure and mechanism of the action of azoles along with the eukaryotic character of fungal pathogens raise several serious issues. Resistance to drugs and disturbance to metabolic pathways are among the most important. On the other hand, these same features are responsible for unique and novel applications of these drugs. As a result, old and ineffective antifungal drugs can be successfully used in the treatment of parasitic diseases, bacterial infections or cancers. Are azoles getting their second wind?
Keywords: Antifungals, azoles, cytochrome P450 fluconazole, off-label use, polypharmacology, resistance, triazoles, drugs, modern medicine
Current Medicinal Chemistry
Title: Azole Antimycotics - A Highway to New Drugs or a Dead End?
Volume: 19 Issue: 9
Author(s): R. Musiol and W. Kowalczyk
Affiliation:
Keywords: Antifungals, azoles, cytochrome P450 fluconazole, off-label use, polypharmacology, resistance, triazoles, drugs, modern medicine
Abstract: Azole antimycotics are a well-known and important class of agents that are used in hospital practice, everyday health care, veterinary medicine and for crop protection. The era of azole fungicides began with the breakthrough of chlormidazole roughly 50 years ago. Since then, more than 20 drugs of this group, including triazoles, have been brought to the market. The specific chemical structure and mechanism of the action of azoles along with the eukaryotic character of fungal pathogens raise several serious issues. Resistance to drugs and disturbance to metabolic pathways are among the most important. On the other hand, these same features are responsible for unique and novel applications of these drugs. As a result, old and ineffective antifungal drugs can be successfully used in the treatment of parasitic diseases, bacterial infections or cancers. Are azoles getting their second wind?
Export Options
About this article
Cite this article as:
Musiol R. and Kowalczyk W., Azole Antimycotics - A Highway to New Drugs or a Dead End?, Current Medicinal Chemistry 2012; 19 (9) . https://dx.doi.org/10.2174/092986712799462621
DOI https://dx.doi.org/10.2174/092986712799462621 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design Blood Pressure Management in Acute Stroke
Current Hypertension Reviews Cytoprotection by Natural and Synthetic Polyphenols in the Heart: Novel Mechanisms and Perspectives
Current Pharmaceutical Design Traumatic Spinal Cord Injury Alters Angiogenic Factors and TGF-Beta1 that may Affect Vascular Recovery
Current Neurovascular Research Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?
Current Cardiology Reviews Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Targeting Insulin Signaling for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Pharmacotherapy During Percutaneous Coronary Intervention in Acute Myocardial Infarction)
Cardiovascular & Hematological Agents in Medicinal Chemistry The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications
Current Diabetes Reviews Design, Synthesis and Biological Study of Novel NO-Donor-Caffeic Acid Hybrids as Potential Anti-Atherosclerotic Drug Candidates
Letters in Drug Design & Discovery Clinical Use of Clopidogrel
Current Pharmaceutical Design Using Extracellular Matrix-Derived Peptides to Alter the Microenvironment for Myocardial Repair
Current Vascular Pharmacology Animal Models for Studying Neointima Formation
Current Vascular Pharmacology Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Clopidogrel in Secondary Ischemic Stroke Prevention
Recent Patents on Cardiovascular Drug Discovery